Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
4033-7 Spironolactone MCnc Urine Pt Qn     DEPRECATED Deprecated Spironolactone [Mass/volume] in Urine   DEL DefinitionDescription                   DRUG/TOX   4033-7                 0 Deprecated Spironolactone Ur-mCnc           Aldactone; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Novospiroton; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.36 1       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
40330-3 Prolactin^15M post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Prolactin [Mass/volume] in Serum or Plasma --15 minutes post dose triple bolus   MIN DefinitionDescription     ng/mL;ug/L             CHAL   40330-3         Observation       0 Prolactin 15M p Triple Bolus SerPl-mCnc       N   15M p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Lactotropic hormone; Lactotropin; Level; Mammatropic hormone; Mammotropin; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PRL; Prol; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip 2.7 2.15               ng/mL       0
40331-1 Prolactin^20M post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Prolactin [Mass/volume] in Serum or Plasma --20 minutes post dose triple bolus   MIN DefinitionDescription     ng/mL;ug/L             CHAL   40331-1         Observation       0 Prolactin 20M p Triple Bolus SerPl-mCnc       N   20M p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Lactotropic hormone; Lactotropin; Level; Mammatropic hormone; Mammotropin; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PRL; Prol; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip 2.7 2.15               ng/mL       0
40332-9 Prolactin^30M post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Prolactin [Mass/volume] in Serum or Plasma --30 minutes post dose triple bolus   MIN DefinitionDescription     ng/mL;ug/L             CHAL   40332-9         Observation       0 Prolactin 30M p Triple Bolus SerPl-mCnc       N   30M p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Lactotropic hormone; Lactotropin; Level; Mammatropic hormone; Mammotropin; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PRL; Prol; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip 2.7 2.15               ng/mL       0
40333-7 Prolactin^1H post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Prolactin [Mass/volume] in Serum or Plasma --1 hour post dose triple bolus   MIN DefinitionDescription     ng/mL;ug/L             CHAL   40333-7         Observation       0 Prolactin 1h p Triple Bolus SerPl-mCnc       N   1 hour; 1.0Hr; 1h p Triple Bolus; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Lactotropic hormone; Lactotropin; Level; Mammatropic hormone; Mammotropin; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PRL; Prol; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip 2.7 2.15               ng/mL       0
40334-5 Somatotropin^pre dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --pre dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40334-5         Observation       0 GH pre Triple Bolus SerPl-mCnc       N   Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre Triple Bolus; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
40335-2 Somatotropin^15M post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --15 minutes post dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40335-2         Observation       0 GH 15M p Triple Bolus SerPl-mCnc       N   15M p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
40336-0 Somatotropin^30M post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40336-0         Observation       0 GH 30M p Triple Bolus SerPl-mCnc       N   30M p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
40337-8 Somatotropin^45M post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40337-8         Observation       0 GH 45M p Triple Bolus SerPl-mCnc       N   45M p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
40338-6 Somatotropin^1H post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40338-6         Observation       0 GH 1h p Triple Bolus SerPl-mCnc       N   1 hour; 1.0Hr; 1h p Triple Bolus; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
40339-4 Somatotropin^2H post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40339-4         Observation       0 GH 2h p Triple Bolus SerPl-mCnc       N   120 min; 120 minutes; 120min; 2 hours; 2h p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
4034-5 Spironolactone MCnc Urine Pt Qn     ACTIVE Spironolactone [Mass/volume] in Urine   MIN DefinitionDescription                   DRUG/TOX   4034-5         Both       0 Spironolactone Ur-mCnc       Y   Aldactone; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Novospiroton; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.34 1                       0
40340-2 Somatotropin^3H post dose triple bolus MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose triple bolus   MIN DefinitionDescription     ug/L;ng/mL             CHAL   40340-2         Observation       0 GH 3h p Triple Bolus SerPl-mCnc       N   3h p Triple Bolus; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; Tri; Trip 2.7 2.15               ng/mL       0
40341-0 MT-ATP6 gene.m.8993T>G PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-ATP6 gene m.8993T>G [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40341-0   Molgen     Both       0 MT-ATP6 m.8993T>G Bld/T Ql       N   ATP synthase 6; ATP synthase A chain; ATP6; ATPASE 6; Blood; Genetics; Heredity; Heritable; Inherited; L156R; Leigh syndrome; Leu156Pro; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTATP6; MT-ATP6 m.8993T>G; NARP syndrome; Neurogenic muscle weakness, ataxia and retinitis pigmentosa; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T8993G; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.T8993G to m.8993T>G since variant is located in a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40342-8 MT-TL1 gene.m.3271T>C PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TL1 gene m.3271T>C [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40342-8   Molgen     Both       0 MT-TL1 m.3271T>C Bld/T Ql       N   Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTL1; MT-TL1 m.3271T>C; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T3271C; T3271G; Tissue; Tissue, unspecified; tRNA leucine 1 (UUA/G); WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.T3271G to m.3271T>C since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines. MtDNA variant 3271T>C is reported in studies (not 3271T>G).; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40343-6 MT-TK gene.m.8296A>G PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TK gene m.8296A>G [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40343-6   Molgen     Both       0 MT-TK m.8296A>G Bld/T Ql       N   A8296G; Blood; Genetics; Heredity; Heritable; Inherited; MERFF syndrome; MERRF syndrome; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTK; MT-TK m.8296A>G; Myoclonic epilepsy and ragged red muscle fibers; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; tRNA lysine; tRNA-lys; WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.A8296G to m.8296A>G since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40344-4 Mttl1 gene.c.A3243G Arb Bld/Tiss Pt Ord     DEPRECATED Deprecated MTTL1 gene c.A3243G [Presence] in Blood or Tissue by Molecular genetics method   DEL DefinitionDescription                   MOLPATH.MUT   40344-4         Both       0 Deprecated MTTL1 c.A3243G Bld/T Ql       N   Arbitrary; Blood; Genetics; Heredity; Heritable; Inherited; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.36 2.15       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
40345-1 MT-TK gene.m.8356T>C PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TK gene m.8356T>C [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40345-1   Molgen     Both       0 MT-TK m.8356T>C Bld/T Ql       N   Blood; Genetics; Heredity; Heritable; Inherited; MERFF syndrome; MERRF syndrome; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTK; MT-TK m.8356T>C; Myoclonic epilepsy and ragged red muscle fibers; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T8356C; T8356GC; Tissue; Tissue, unspecified; tRNA lysine; tRNA-lys; WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.T8356GC to m.8356T>C since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40346-9 MT-CO1 gene.m.7445A>G PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-CO1 gene m.7445A>G [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40346-9   Molgen     Both       0 MT-CO1 m.7445A>G Bld/T Ql       N   Blood; COI; cytochrome c oxidase I gene; Cytochrome c oxidase polypeptide I gene; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTCO1; MT-CO1 m.7445A>G; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.A7445G to m.7445A>G since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40347-7 MT-TL1 gene.m.3256C>T PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TL1 gene m.3256C>T [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40347-7   Molgen     Both       0 MT-TL1 m.3256C>T Bld/T Ql       N   Blood; C3256T; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTL1; MT-TL1 m.3256C>T; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T prime; Tissue; Tissue, unspecified; tRNA leucine 1 (UUA/G); WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.C3256T to m.3256C>T since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40348-5 MT-TL1 gene.m.3252T>C PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TL1 gene m.3252T>C [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40348-5   Molgen     Both       0 MT-TL1 m.3252T>C Bld/T Ql       N   Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTL1; MT-TL1 m.3252T>C; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T3252C; Tissue; Tissue, unspecified; tRNA leucine 1 (UUA/G); WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.T3252C to m.3252T>C since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40349-3 MT-TK gene.m.8363G>A PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TK gene m.8363G>A [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40349-3   Molgen     Both       0 MT-TK m.8363G>A Bld/T Ql       N   Blood; G8363A; Genetics; Heredity; Heritable; Inherited; MERFF syndrome; MERRF syndrome; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTK; MT-TK m.8363G>A; Myoclonic epilepsy and ragged red muscle fibers; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; tRNA lysine; tRNA-lys; WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.G8363A to m.8363G>A since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
4035-2 Spironolactone MRat Urine 24H Qn     ACTIVE Spironolactone [Mass/time] in 24 hour Urine   MIN DefinitionDescription                   DRUG/TOX   4035-2         Both       0 Spironolactone 24h Ur-mRate       Y   1 day; 24 hours; 24HR; Aldactone; DRUG/TOXICOLOGY; Drugs; Mass rate; mRate; Novospiroton; QNT; Quan; Quant; Quantitative; UA; UR; Urn 2.19 1                       0
40350-1 MT-TL1 gene.m.3291T>C PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-TL1 gene m.3291T>C [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40350-1   Molgen     Both       0 MT-TL1 m.3291T>C Bld/T Ql       N   Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTTL1; MT-TL1 m.3291T>C; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T3291C; Tissue; Tissue, unspecified; tRNA leucine 1 (UUA/G); WB; Whole blood; Whole blood or Tissue 2.56 2.15                     Changed Component part from c.T3291C to m.3291T>C since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
40351-9 MT-ND4 gene.m.11778G>A PrThr Bld/Tiss Pt Ord Molgen   ACTIVE MT-ND4 gene m.11778G>A [Presence] in Blood or Tissue by Molecular genetics method   MIN DefinitionDescription                   MOLPATH.MUT   40351-9   Molgen     Both       0 MT-ND4 m.11778G>A Bld/T Ql       N   Blood; G11778A; Genetics; Heredity; Heritable; Inherited; Leber hereditary optic neuropathy; LHON; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTND4; MT-ND4 m.11778G>A; NADH dehydrogenase subunit 4; NADH ubiquinone oxidoreductase subunit ND4; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; R304H; Random; Screen; Spastic dystonia; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue 2.73 2.15                     Changed Component part from c.G11778A to m.11778G>Asince variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
104,672 results found